Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Zevra Therapeutics, Inc. has 5 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Zevra Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 11.65 · gapped above the open, then crossed back over prior close. High/low 12.00 at 7:15 am ET, 11.56 at 3:00 pm ET.
Zevra Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
ZVRA (Zevra Therapeutics, Inc.) has 5 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under our March 2012 termination agreement with Aquestive Therapeutics ("Aquestive"), Aquestive has the right to receive a royalty amount equal to 10% of any value generated by AZSTARYS and any product candidates containing SDX.”
$11M relationship
basisZVRA fy2025 · closed 2025-12 $106M
FILING10-K0001434647-26-000011cik 0001434647
“Pursuant to the Relief License Agreement, Zevra is obligated to pay royalties of 10% of U.S. net sales up to a maximum of $45.0 million, plus specified regulatory milestones, for total payments to Relief of up to $56.5 million.”
$11M relationship
basisZVRA fy2025 · closed 2025-12 $106M
FILING10-K0001434647-26-000011
“In May 2022, we purchased all the assets and operations of Orphazyme A/S ("Orphazyme") related to arimoclomol.”
FILING10-K0001434647-26-000011cik 0001434647
“Under the XOMA License Agreement, we paid a $6.0 million regulatory milestone payment earned by XOMA upon the approval of MIPLYFFA on September 20, 2024.”
FILING10-K0001434647-26-000011cik 0001434647
“Under the AZSTARYS License Agreement, Corium is responsible for these regulatory activities going forward, and we cannot guarantee they will be complied with.”
FILING10-K0001434647-26-000011cik 0001434647
“We entered into the AZSTARYS License Agreement with Commave pursuant to which we granted an exclusive, worldwide license to Commave to develop, manufacture and commercialize AZSTARYS.”
FILING10-K0001434647-26-000011cik 0001434647
Watchlist prices, news filtered to it, and its next report on your desk.